science behind the idea . In fact , this isn ’ t a privilege held by anyone since DiaMonTech ’ s technology is patented .
Mäntele asserts : “ We would take care not to be swallowed up , and we are not selling the idea for a lump of money . If what we achieved was noticed by big players , then we would use investment to increase our employees and so on . The central principle is all ours . However , big corporations like Apple , Samsung and Nokia are very good at building small , often elegant devices for the mass market and selling several millions of devices . As a startup we don ’ t have their know-how , so of course we would consider a partnership .”
Once all of DiaMonTech ’ s products have been completed and tested , how then will the devices make in onto the shop floors at the local drugstore , in the same way that blood pressure testing devices have done ? Mäntele believes that there is no problem with the technology reaching those who need it most , and maintains that it will be promoted and distributed accordingly .
He enthuses : “ We get pre-orders , and the diabetic patient community is very well organised with a developed information flow – they have their own journals . The community knows about new products , and due to their marketing of them , micro non-invasive blood measuring products would sell like hotcakes .”
With more work by scientists like Mäntele and further success for DiaMonTech , which won the 2017 “ most innovative startup ” award from German magazine Bilanz , we could soon see test-strips and finger pricking become a thing of the past for this $ 35.5bn market .
33